NEWARK, Del., Aug. 14, 2026 — The global EZH2 Inhibitors Market is entering a significant development phase as pharmaceutical and biotechnology companies advance epigenetic therapies for hematologic malignancies and other oncology indications. According to Future Market Insights (FMI), the market is projected to grow from USD 1.3 billion in 2026 to USD 4.2 billion by 2036, registering a...